Am J Clin Dermatol (2014) 15 (Suppl 1):S3–S4 DOI 10.1007/s40257-013-0058-0
FOREWORD
Foreword Alice Bendix Gottlieb
Ó Springer International Publishing Switzerland 2014
Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. There are currently five marketed TNF inhibitors; infliximab, etanercept, adalimumab, golimumab and certolizumab. TNF inhibitors clear psoriasis, control signs and symptoms of psoriatic arthritis, inhibit radiographic progression and improve quality of life in both psoriasis and psoriatic arthritis [1–11]. Some registry data suggest protection from cardiovascular morbidity and mortality although there is controversy in this area [12–14]. Much data exist from clinical trials, however there are fewer publications on the use in clinical practice. This supplement focuses on the use of infliximab in clinical practice. Infliximab is the only TNF blocker which is given intravenously and which has weight-based dosing. The article in this supplement by Eusebio et al. [15] reviews the use of biologics for psoriasis and describes their experience treating psoriasis patients in hospitalbased or specialized infusion center-based clinics. The article by Mun˜oz et al. [16] details a number of case reports describing the use of infliximab in an infusion center. Acknowledgments This article was published in a supplement sponsored by the Inflammatory Autoimmunes Diseases Catedra of University of Alcala´, Madrid, Spain. The supplement was guest edited by Alice Bendix Gottlieb and Kristian Reich and peer reviewed by Enzo Berardesca and Howard Maibach, all of whom received honoraria to cover out of pocket expenses. A.B.G currently holds consulting or advisory board agreements with Amgen Inc., Astellas, Centocor (Janssen) Inc., Celgene Corp., Bristol Myers Squibb Co., Beiersdorf Inc., Abbot Labs (AbbVie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd., Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, and Glaxo Smith Kline. She has also received research and/or educational grants from Centocor (Janssen), Amgen, Abbott (AbbVie), Novartis, Celgene, Pfizer, Lilly, Coronado, and Levia. K.R. has received honoraria as a consultant and/or advisory board member and/ or acted as a paid speaker and/or participated in clinical trials
sponsored by AbbVie, Amgen, Biogen-Idec, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Lilly, Medac, MSD, Novarti, Ocean Pharma, Pfizer, Takeda, and Vertex. E.B. and H.M. have no conflicts of interest to declare.
References 1. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003;48(6): 829–35. 2. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357: 1842–7. 3. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31 e1–15. 4. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. NEJM. 2003;349(21): 2014–22. 5. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–32 (discussion 32). 6. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15. 7. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55. doi:10.1136/annrheumdis-2013-203696. 8. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthr Rheum. 2012;64(8):2504–17. 9. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–90. 10. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic
S4 arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthr Rheum. 2005;52(10):3279–89. 11. Kavanaugh A, Antoni CE, Gladman D, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65(8): 1038–43. 12. Wu JJ. Tumor necrosis factor inhibitors and myocardial infarction in psoriasis. JAMA. 2013;310(10):1075–6. 13. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthr Rheum. 2007;56(9):2905–12.
A. B. Gottlieb 14. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–82. 15. de Eusebio E, Armario-Hita JC, de Miquel DVA. Treatment of Psoriasis: focus on clinic-based management with Infliximab. Am J Clin Dermatol. 2014. doi:10.1007/s40257-013-0054-4. 16. Campos Mun˜oz L, de Unamuno Bustos B, Herranz Pinto P, et al. Infliximab treatment of Psoriasis in supervised infusion centers: case management experience. Am J Clin Dermatol. 2014. doi:10. 1007/s40257-013-0055-3.
FOREWORD
Foreword Alice Bendix Gottlieb
Ó Springer International Publishing Switzerland 2014
Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. There are currently five marketed TNF inhibitors; infliximab, etanercept, adalimumab, golimumab and certolizumab. TNF inhibitors clear psoriasis, control signs and symptoms of psoriatic arthritis, inhibit radiographic progression and improve quality of life in both psoriasis and psoriatic arthritis [1–11]. Some registry data suggest protection from cardiovascular morbidity and mortality although there is controversy in this area [12–14]. Much data exist from clinical trials, however there are fewer publications on the use in clinical practice. This supplement focuses on the use of infliximab in clinical practice. Infliximab is the only TNF blocker which is given intravenously and which has weight-based dosing. The article in this supplement by Eusebio et al. [15] reviews the use of biologics for psoriasis and describes their experience treating psoriasis patients in hospitalbased or specialized infusion center-based clinics. The article by Mun˜oz et al. [16] details a number of case reports describing the use of infliximab in an infusion center. Acknowledgments This article was published in a supplement sponsored by the Inflammatory Autoimmunes Diseases Catedra of University of Alcala´, Madrid, Spain. The supplement was guest edited by Alice Bendix Gottlieb and Kristian Reich and peer reviewed by Enzo Berardesca and Howard Maibach, all of whom received honoraria to cover out of pocket expenses. A.B.G currently holds consulting or advisory board agreements with Amgen Inc., Astellas, Centocor (Janssen) Inc., Celgene Corp., Bristol Myers Squibb Co., Beiersdorf Inc., Abbot Labs (AbbVie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd., Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, and Glaxo Smith Kline. She has also received research and/or educational grants from Centocor (Janssen), Amgen, Abbott (AbbVie), Novartis, Celgene, Pfizer, Lilly, Coronado, and Levia. K.R. has received honoraria as a consultant and/or advisory board member and/ or acted as a paid speaker and/or participated in clinical trials
sponsored by AbbVie, Amgen, Biogen-Idec, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Lilly, Medac, MSD, Novarti, Ocean Pharma, Pfizer, Takeda, and Vertex. E.B. and H.M. have no conflicts of interest to declare.
References 1. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003;48(6): 829–35. 2. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357: 1842–7. 3. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31 e1–15. 4. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. NEJM. 2003;349(21): 2014–22. 5. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–32 (discussion 32). 6. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15. 7. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55. doi:10.1136/annrheumdis-2013-203696. 8. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthr Rheum. 2012;64(8):2504–17. 9. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–90. 10. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic
S4 arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthr Rheum. 2005;52(10):3279–89. 11. Kavanaugh A, Antoni CE, Gladman D, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65(8): 1038–43. 12. Wu JJ. Tumor necrosis factor inhibitors and myocardial infarction in psoriasis. JAMA. 2013;310(10):1075–6. 13. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthr Rheum. 2007;56(9):2905–12.
A. B. Gottlieb 14. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–82. 15. de Eusebio E, Armario-Hita JC, de Miquel DVA. Treatment of Psoriasis: focus on clinic-based management with Infliximab. Am J Clin Dermatol. 2014. doi:10.1007/s40257-013-0054-4. 16. Campos Mun˜oz L, de Unamuno Bustos B, Herranz Pinto P, et al. Infliximab treatment of Psoriasis in supervised infusion centers: case management experience. Am J Clin Dermatol. 2014. doi:10. 1007/s40257-013-0055-3.
